A 5 amino-acid insertion in the C-terminal region of HIV-2 integrase impacts phenotypic susceptibility to the five integrase inhibitors- Quentin Le Hingrat

European Meeting on HIV & Hepatitis 2018

A new wild-type HIV in the era of transmitted drug resistance- Kristof Theys, PhD

European Meeting on HIV & Hepatitis 2018

Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca Lombardi

European Meeting on HIV & Hepatitis 2018

Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander Thielen

European Meeting on HIV & Hepatitis 2018

Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria Santoro

European Meeting on HIV & Hepatitis 2018

Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van Kampen

European Meeting on HIV & Hepatitis 2018

Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhD

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCP

European Meeting on HIV & Hepatitis 2018

Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhD

European Meeting on HIV & Hepatitis 2018

Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim Fourati

European Meeting on HIV & Hepatitis 2018

Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia Barbaliscia

European Meeting on HIV & Hepatitis 2018

Acute hepatitis A to E, diagnosis and management - Thomas Berg, MD

European Meeting on HIV & Hepatitis 2018

B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhD

European Meeting on HIV & Hepatitis 2018

Clinical development of ABX464, drug candidate for HIV functional cure- Jean-Marc Steens, MD

European Meeting on HIV & Hepatitis 2018

Reduced drug regimens- Andrea De Luca, MD

European Meeting on HIV & Hepatitis 2018

What is the place of the monoclonal antibodies in the clinic- Julià Blanco, PhD

European Meeting on HIV & Hepatitis 2018

Comparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients - Le

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2018

Integrating science, logistics and cost in approval of hierarchical testing strategies for NASH - The payer's perspective- Robert LoNigro, MD

International Workshop on NASH Biomarkers 2018

Pathways and priorities for biomarker assessment- Peter Stein, MD

International Workshop on NASH Biomarkers 2018

Repeatability, reproducibility and analytic standards for biomarker development- Abbas Bandukwala

International Workshop on NASH Biomarkers 2018

Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhD

International Workshop on NASH Biomarkers 2018

Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhD

International Workshop on NASH Biomarkers 2018

Quality standards for imaging studies- Claude Sirlin, MD

International Workshop on NASH Biomarkers 2018

Case definitions for use as reference standards- Mohammed Siddiqui, MD

International Workshop on NASH Biomarkers 2018